

FINANCES: What resources were available to support the national program in the past six years? And what resources are available in the coming three years?

OUTCOME: How many people received the treatment and prevention services that they need?

IMPACT: What is the trend among people who continue to fall ill or die? (actual and hypothetical in the absence of program)


Historical investments by funding source (2012-2017)

Global Fund investments:
2014-2016 Allocation period
 Tuberculosis disbursements: **\$57.8m**

2017-2019 Allocation period
 Tuberculosis disbursements: **\$46.3m**


Cross-cutting RSSH disbursements: **\$46.9m** Cross-cutting RSSH disbursements: **\$28.6m**

In 2015-2017, **51%** of NSP need was funded.



¹Domestic – National Health Accounts, funding request submitted to the Global Fund; External – country reported, OECD DAC CRS

Planned investments by funding source and intervention (2018-2020)²




²Detailed financial gap analysis reported by country based on Global Fund Modules




Global Fund Results (2019)

People with TB treated: **111k** People with drug-resistant TB on treatment: **604** HIV+ TB patients on ART: **4.71k**

TB case finding and treatment coverage




TB treatment outcomes




TB deaths (excluding HIV+)

Change in TB deaths (excluding HIV+):
35% reduction from 2012 to 2019
62% reduction from 2000 to 2019



New TB cases (all forms)

Change in TB cases:
29% reduction from 2012 to 2019
44% reduction from 2000 to 2019



Notes
 Detailed notes are available on the separate Explanatory Notes page
https://www.theglobalfund.org/media/7871/other_countryresultsprofileexplanatory_notes_en.pdf